Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library

School of Medicine

1992

An inhibitor of angiogenesis isolated from bovine
cornea
Elizabeth Anne Mullen
Yale University

Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
Recommended Citation
Mullen, Elizabeth Anne, "An inhibitor of angiogenesis isolated from bovine cornea" (1992). Yale Medicine Thesis Digital Library. 2968.
http://elischolar.library.yale.edu/ymtdl/2968

This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.

YALE UNIVERSITY LIBRARY

'!$■*j'i

i-aasss
AN INHIBITOR OF ANGIOGENESIS
ISOLATED FROM BOVINE CORNEA

ELIZABETH ANNE MULLEN

YALE

MEDICAL LIBRARY

Digitized by the Internet Archive
in 2017 with funding from
The National Endowment for the Humanities and the Arcadia Fund

https://archive.org/details/inhibitorofangioOOmull

AN INHIBITOR OF ANGIOGENESIS
ISOLATED
FROM BOVINE CORNEA

Elizabeth Anne Mullen

A thesis in partial fulfillment of the requirements for the degree

Doctor of Medicine

Yale University School of Medicine
Department of Orthopaedics and Rehabilitation

1992

U<?d Lit
-tf

13

t fl X

DEDICATION

With gratitude and love to my parents,
Katherine and John Mullen, for their boundless
support and encouragement.

i

TABLE OF CONTENTS

DEDICATION.

i

TABLE OF CONTENTS.

i i

ABSTRACT.

i ii

INTRODUCTION.

1

METHODS.

1 2

RESULTS.

1 8

DISCUSSION.

24

TABLES.

32

FIGURES.

39

REFERENCES.

50

ii

ABSTRACT

AN INHIBITOR OF ANGIOGENESIS ISOLATED FROM BOVINE CORNEA.
Elizabeth A. Mullen, Rosalind A. Rosenthal, 'Peter V. Hauschka and
Judah

Folkman.

Hospital,

Department of Surgical Research, Children's

Boston,

MA,

'Department

Children's Hospital, Boston, MA.

of

Orthopedic

Research,

(Sponsored by Caren M. Gundberg,

Department of Orthopaedics and Rehabilitation, Yale University
School of Medicine, New Haven, CT).

The

normally

avascular

cornea

paradoxically

contains

stores of a potent stimulator of angiogenesis, basic fibroblast
growth factor (bFGF) (Am. J. Path. 130:393, 1988).

Mun et al.

reported the partial purification from bovine cornea of a low
molecular weight molecule which

inhibits angiogenesis

chick embryo (Inv Opth & Vis Sci. 30:151, 1989).

in the

This factor,

termed corneal angiogenesis inhibitor (CAI), was also shown to
antagonize certain bFGF induced effects on capillary endothelial
cells, including cell migration, cell spreading and cell rounding.
Endothelial cell rounding in vitro has been correlated with anti¬
angiogenesis in vivo (Endocrinology 119:1768, 1986).

We report

an improved purification method for CAI, which like Mun et al.
used the ability of CAI to cause endothelial cell rounding to
direct purification.

We also

measured the ability of CAI to

inhibit DNA synthesis in endothelial cells, and block angiogenesis
on the chorioallantoic membrane of chick embryos.

Our improved

purification produced a sample sufficiently pure for preliminary
structural analysis.

This method includes:

bovine corneas;

Extraction

Filtration

of

(2)

corneas

into

and

cutoff,

and

centrifugation

dimethylformamide

lyophilization;
(DMF),

Dissection of

100°C distilled water; (3)

Ultrafiltration through pressure dialysis,
(MW)

(1)

of

filtrate;

(4)

1000 molecular weight

(5)

Extraction

centrifugation

and

in

80%

evaporation

of

solvent; (6) 100% DMF extraction, centrifugation and evaporation
of

solvent;

(7)

Reversed

phase

high

performance

liquid

chromatography on both a Cl8 semi-preparative column and a Cl8
analytical

column.

Samples

purified

by

this

method

were

analyzed by desorptive chemical ionization and electospray mass
spectroscopy.

Possible candidates for the CAI molecule were

identified at MW 228 and 172.

CAI may play an important role in

the regulation of vascularization in the cornea, perhaps acting as
an endogenous inhibitor of bFGF.

IV

INTRODUCTION

The regulation of vascularization is of great importance in
many normal physiologic and pathologic processes.

The term

"angiogenesis" was introduced in 1935 to describe the formation
of new blood vessels in the placenta

(Hertig,

1935).

It is

currently used to denote the process of generating new capillary
blood

vessels

from

"neovascularization".

established
Under

vessels,

normal

resulting

physiologic

in

conditions,

angiogenesis has an essential role in embryonic development,
ovulation, placental maturation, and wound healing (Jakob et al.,
1977; Gospodarowicz and Thakral,

1978; Wagner,

1980;

Bar,

1980; Hunt et al., 1981).

Abnormal neovascularization dominates a number of serious
pathologic conditions, both malignant and nonneoplastic.
evidence

exists

that

solid

tumor

growth

is

Much

angiogenesis

dependent (reviewed in Folkman, 1990; Klagsbrun and Folkman,
1990) .

Tumor angiogenesis and the incidence of metastasis in

invasive breast carcinoma are highly correlated (Weidner et al.,
1991) .

Many diverse diseases (Table 1) in which the dominant

pathology is persistent neovascularization have been categorized
as "angiogenic disease" (Folkman and Klagsbrun, 1987).

Patients

affected by angiogenic diseases span a wide range of ages, and
include both sexes.

Care and management of these conditions are

divided among numerous medical and surgical specialties.

For

example,

the

the

excessive

proliferation
1

and

shedding

of

epidermis in psoriasis has been related to abnormal capillary
growth in the dermis (Ryan, 1970).

Hemangiomas can occur in

newborn babies, with abnormal capillary proliferation persisting
until up to two years of age, and which in rare cases may result
in

death

from

hemorrhage

Klagsbrun, 1987).

(

Folkman,

1984;

Folkman

and

All hemangiomas are known to eventually

regress spontaneously; the mechanism through which this occurs
is

completely

unknown.

Atherosclerotic

plaques

can

bleed

secondary to capillary proliferation within the vessel wall, and
contribute to sudden occlusion of coronary arteries (Barger et al.,
1984).

Abnormal
avascular
occurrence

neovascularization

tissue,
of

as

in

capillary

can

also

rheumatoid
growth

affect

arthritis,

destroys

normally

where

joint

the

cartilage

(Matsubara and Ziff, 1987; Koch et al., 1986; Crisp et al., 1984).
Neovascularization in avascular components of the eye leads to
decreased vision or blindness.

Diabetic retinopathy, retrolental

fibroplasia, and neovascular glaucoma are pathologic conditions
which involve a breach of the vascular/avascular barriers within
the eye (Klagsbrun and Folkman, 1990).

Disorders involving either

the corneal epithelium or stroma (Table 2) can result in invasion
of blood vessels into the avascular corneal stroma, and are a
leading cause of blindness worldwide (Garner, 1986).

The

control

of

the

stimulation

and

angiogenesis has been extensively investigated.
2

inhibition

of

A picture has

.

emerged

of a

regulatory

system

analogous

to

other

known

physiologic processes, such as blood coagulation (Folkman and
Klagsbrun, 1987).

Both systems must be maintained in a state of

inactivity, but constant readiness, over a long period of time.

The

proliferation of vascular endothelial cells in most normal adult
tissue is measured with turnover time in years (Denekamp, 1984),
congruent with

a

microvascular

system

designed

quiescent over periods of weeks to decades.

to

remain

The microvascular

system, however, must be capable of prompt response when faced
with pathologic conditions or physiologic demands which require
the rapid growth of new vessels.

The

search

for factors

which

angiogenesis has been extensive.

may

stimulate

or

inhibit

A number of factors, including

polypeptides and nonpeptide low molecular weight compounds,
have been shown to be angiogenic in vivo
1990) (Table 3).
complex.

(Klagsbrun and Folkman,

The process of angiogenesis in vivo

is very

Many sequential steps are required: the degradation of

capillary basement membrane, the migration and proliferation of
endothelial

cells,

and

tube

formation.

described stimulators of cell division,
factor (bFGF)

One

of the

earliest

basic fibroblast growth

has been found to be a potent stimulator of

endothelial cell growth and angiogenesis.

The term FGF was first

used to describe a cationic polypeptide isolated from brain in
1974

(Gospodarowicz,

1974,

1975);

its

primary

structure was described in 1985 (Esch et al., 1985).

amino

acid

An anionic

species of FGF, which was termed acidic fibroblast growth factor
3

(aFGF) was also found in brain, and shown to have a 53% absolute
sequence homology to the cationic polypeptide, which became
known as bFGF (Thomas et al., 1980; Lemmon and Bradshaw, 1983;
Thomas 1987; Esch et al., 1985). The FGFs have since been shown
to be mitogenic and chemotactic for endothelial cells in vitro, to
stimulate endothelial cells to produce proteases (collagenase and
plasminogen activator) which result in degradation of basement
membrane, and to induce capillary endothelial cells to migrate
into three-dimensional collagen matrices and form tubes similar
to capillaries (Gross et al., 1983; Montesano et al., 1986).

These

demonstrated in vitro properties of the FGFs are consistent with
their observed angiogenic activity in vivo.

The FGFs are among the most ubiquitous growth factors in
the body (Folkman and Klagsbrun, 1987).

bFGF is found in brain

(Lobb and Fett, 1984; Gospodarowicz et al., 1984; Bohlen et al.,
1984),

eye

(Courty

et al.,

1985),

cartilage

Klagsbrun, 1985), bone (Hauschka et al.,

(Sullivan

and

1986), reproductive

tissue (Moscatelli et al., 1986), adrenal gland (Gospodarowicz et
al., 1986), kidney (Baird et al., 1985a), macrophages (Baird et al.,
1985b) and tumors (Shing et al., 1984; Klagsbrun et al., 1986),
while aFGF is present mainly in neural tissue including brain
(Lobb and Fett, 1984; Thomas et al., 1984; Conn and Hatcher,
1984), retina (D'Amore and Klagsbrun, 1984), and eye (Courty et
al., 1985), and has also been identified in bone (Klagsbrun and
Folkman, 1990).

This extensive distribution raises the question

of how rampant capillary proliferation
4

is

prevented

in

both

normally vascular, and particularly, in normally avascular tissue.
This question, in turn, has prompted the search for naturally
occurring inhibitors of angiogenesis.

The first angiogenesis inhibitor was found in the normally
avascular cartilage (Eisenstein et al., 1973; Brem and Folkman,
1975), and has recently been characterized and identified as
(Moses et al., 1990).

cartilage-derived inhibitor (CDI)
member

of

the

tissue

inhibitor

of

CDI is a

metalloproteinase

(TIMP)

family, and has been shown to inhibit angiogenesis in vivo, and
capillary

endothelial

cell

proliferation

and

migration

(Moses and Langer, 1991; Moses et al., 1990).
an

inhibitor of mammalian

collagenase.

naturally-occurring

inhibitors

identified.

factors

prolactin

These
(Ferrara

of

include

This protein is also

A number of other

angiogenesis
the

in vitro

16

kDa

have

been

fragment

of

et al., 1991), thrombospondin (Good et al.,

1990; Bagavandoss and Wilks, 1990; Taraboletti et al.,

1990),

platelet factor 4 (Maione et al., 1990), and protamine (Taylor and
Folkman, 1982).

Transforming growth factor-beta (TGF-B) (Baird

and Durkin, 1986; Muller et al., 1987; Jennings et al., 1988), and
tumor

necrosis

factor-alpha

(TNF-a)

(Frater-Schroder

et al.,

1987; Schweigerer et al., 1987) are both polypeptides that inhibit
endothelial cell proliferation in vitro, yet promote angiogenesis

in vivo and tube formation in vitro .
TGF-B

It is possible that TNF-a and

may inhibit the proliferative phase of endothelial cells,

but promote the differentiation phase, e.g., matrix production and
tube formation (Klagsbrun and Folkman, 1990).
5

To date, none of these known angiogenesis inhibitors have
been found in the avascular structures of the eye.
evidence

exists

to

support

the

occurrence

However, much
of

endogenous

inhibition of angiogenesis within the eye.

The eye contains both vascular and avascular structures
(Figure 1).

The sclera, which comprises the posterior four-fifths

of the surface of the globe, is composed largely of collagen,
proteoglycan and fibroblasts.

Interestingly, although the sclera

is interposed between two highly vascular tissues, the episclera
and the choroid, it is avascular.

Inflammatory diseases of the

ocular surface involving macrophages and bFGF containing mast
cells, which often result in corneal neovascularization, do not
cause scleral neovascularization (Sunderkotter et al., 1991).

This

could be attributed to the presence of a potent endogenous
inhibitor(s) in the sclera.

Alternatively, there could be physical

or mechanical resistance to angiogenesis in the sclera.

The fetal lens contains hyaloid vessels during embryonic
development; these regress shortly before birth.

Human lens

epithelium has been shown to contain angiogenic aFGF (Baudouin

et al., 1990).

Paradoxically, extracts of both human and bovine

lens demonstrate a reversible dose-dependent inhibition of bovine
aorta endothelial cell proliferation in vitro.

This result suggests

that an extractable, endogenous inhibitor of angiogenesis also
exists (Williams et al., 1984).

It has also been shown that the

removal of lens and capsule in proliferative diabetic retinopathy
6

leads to an increased incidence of iris neovascularization (Aiello

et al., 1983).

Numerous mechanisms to explain this phenomenon

have been postulated, including facilitated diffusion of a retinal
"vasoformative factor" (Ashton, 1957), decreased oxygenation of
the iris and release of an "iris vasoformative factor" (Schulze,
1967), and reduced endogenous inhibition from the lens (Williams

et al., 1984).

The aqueous
physically

contacts

humor
the

trabecular meshwork.

fills

the

cornea,

anterior

lens,

iris,

chamber,

ciliary

body

and
and

It has been demonstrated that normal

aqueous humor inhibits capillary endothelial cell proliferation in

vitro, while it promotes a dose-dependent proliferation of 3T3
smooth muscles cells and dermal fibroblast in vitro (Okamoto et

al.,

1990).

Interestingly,

it was

also

found

that

this

anti-

angiogenic activity is absent in the aqueous humor of diabetic
rabbits.

The identity or source of the proposed endogenous

inhibitor has not been elucidated.

The vitreous humor occupies the chamber anterior to the
retina and posterior to the
collagen,

hyalocytes,

and

lens.
the

It is composed of water,

proteoglycan

hyaluronic

acid.

Clinically, the vitreous appears to be resistant to angiogenesis.
In proliferative diabetic retinopathy, fronds of developing blood
vessels grow onto the vitreous surface, but do not penetrate its
substance.
diabetic

Interestingly,

proliferative

the

retinopathy
7

vitreous
has

been

from

patients

shown

to

with

contain

elevated

levels

of

bFGF

(Sivalingam et al.,

1990).

This

observation suggests the possibility of an increase in the ratio of
angiogenesis
disease.

stimulators to

inhibitors

in

the

vitreous

in

this

As evidence of the angiogenic potential of the vitreous,

degradation products of vitreous hyaluronic acid assayed on the
chick chorioallantoic membrane (CAM) were shown to
neovascularization

(West

et at., 1985).

induce

However, vitreous has

also been shown to be inhibitory of angiogenesis.

Angiogenic

tumors implanted into the vitreous remain small and avascular unless they happen into direct contact with the retina (Brem et

al., 1976).
both

Extracts from the vitreous have been shown to inhibit

retinal

extract-induced

angiogenesis
concept

of

stimulatory

(Lutty

et al., 1985).

regulatory
factors

angiogenesis,

interplay

of

and

tumor-induced

These findings support the
between

angiogenesis

both

inhibitory

which,

under

and

normal

conditions, maintain an avascular state in the vitreous.

Neovascularization of the retina is a serious consequence of
several

pathologic

conditions;

diabetes,

sickle

cell

anemia,

branch vein occlusion, and retrolental fibroplasia (Patz,

1982).

Blindness

retinal

results

from

vitreous

hemorrhage

and

detachment following the development of new blood vessels in
the

retina

(Ashton,

1983).

Studies

have

shown

that

retina

contains endothelial cell growth factors, including aFGF and bFGF
(Baird et al., 1985), as well as serum factors such as platelet
release factors (Miyazono et al., 1987), and insulin-like growth
factors (Grant et al., 1987; King et al., 1985).
8

However, more

recently

McIntosh and co-workers showed that retinal extract

inhibited

the

serum-induced

proliferation

endothelial cells (McIntosh et al., 1989).

of

retinal

capillary

This finding suggests a

regulatory system for vascularization within the retina involving
a balance of angiogenesis stimulators and inhibitors.

The normally avascular cornea is paradoxically known to
contain large stores of angiogenic bFGF (Folkman et al., 1988).
The bFGF has been shown to bind to Bowman's layer, the acellular,
most anterior portion of the collagenous corneal stroma, which is
rich in proteoglycan (Adamis et al., 1991).

BFGF is also found in

Descemet's membrane, a true basement membrane produced by
corneal endothelial cells on the posterior surface of the cornea
(Figure 2).

Folkman and co-workers demonstrated that bFGF could

be released from the cornea by treatment with heparin, heparan
sulfate,

or

suggested

heparanase
that

(Folkman

sequestration

of

et al., 1988).
this

Their work

angiogenic

endothelial

mitogen in the basement membrane could be a general mechanism
for controlling the accessibility of bFGF to vascular endothelium,
therefore regulating vascularization.

The abnormal release of

bFGF could be the cause of corneal vascularization in a number of
ocular diseases.

In

support of this

concept,

injury-induced

release of bFGF from corneal epithelial cells has recently been
demonstrated (Adamis et al., 1991).

As

an

alternate,

or

additional

explanation

for

the

maintenance of avascularity of the cornea in the presence of
9

angiogenic bFGF, the existence of an angiogenesis inhibitor in the
cornea was hypothesized.
hypothesis.

Corneal

A number of studies supported this

extracts

which

were

mitogenic

for

endothelial cells were found to be inhibitory of cell growth at
high concentrations (Folkman et al., 1988).

When pieces of cornea

from several animal species were placed onto the chorioallantoic
membrane (CAM) of a developing chick embryo (Folkman, Casey,
Levenson, unpubl. results), avascular zones appeared around the
corneas.

These corneas could be moved to another chick embryo,

and again, an avascular zone on the CAM surrounding the cornea
would be produced. This suggested the production of a diffusible
angiogenesis inhibitor by the cornea.

A systematic search for this corneal angiogenesis inhibitor,
termed CAI, was undertaken.

A partial purification scheme was

established by Susan Doctrow, Edward Mun, and Judah Folkman,
and many characteristics of the molecule defined.

The inhibitor

was found to stable to boiling and pronase digestion.
amino

acid

analysis

techniques

revealed

indicating the inhibitor is not a peptide.

no

Sensitive

amino

acids,

Bioactivities of the

partially purified CAI were also characterized.

In addition to the

inhibition of angiogenesis on the CAM assay, CAI was shown to
cause

inhibition

of

DNA

synthesis

in

endothelial

cells,

and

inhibition of bFGF stimulated cell migration, in a Boyden chamber
model

(Mun

et al., 1989).

Partially purified CAI blocks both

attachment (cell number analysis) and cell spreading of bovine
capillary

endothelial

(BCE)

cells
10

in

response

to

bFGF

(morphometric

analysis)

(Carter,

Ingber,

Folkman,

unpubl.).

Staining with antibodies to vimentin demonstrates disconnection
of

the

intermediate

filaments

from

the

plasma

followed by the depolarization of actin.
inhibition

of cell spreading,

corneal

membrane,

Associated with the

extracts can

also

cause

endothelial cells to "round", in a dose-dependent manner.
rounding effect can be reversed by titration with bFGF.

This

Rounded

cells exclude trypan blue, and stain with fluorescein diacetate,
indicating viability.

Inhibition of cell migration was observed

with the lowest quantities of CAI, followed by DNA synthesis
inhibition, and endothelial cell rounding.

Angiogenesis inhibition

on the CAM required the most material.

A semi-quantitative
rounding

effect

of

screening

CAI

was

assay

designed

based

to

guide

purification of this molecule (Mun et at., 1989).
purification

was

reproducibility

of

hampered
results,

by

inconsistent

particularly

in

on

the

the

cell

further

In large part, the
behaviors

achieving

and

binding

to

high-pressure liquid chromatography (FIPLC) column resins.

In our work, we have further improved the purification of
CAI,

while

retaining

ultrafiltration,

organic

its

bioactivity.

extraction,

and

Aqueous
reverse

extraction,
phase

high-

pressure liquid chromatography were used to reproducibly obtain
a

partially

pure

preparation

analysis by mass spectroscopy.

of

CAI,

suitable

for

preliminary

METHODS

Cell Culture -

Bovine capillary endothelial (BCE) cells were

isolated from bovine adrenal glands as described by Folkman et

al., (1979), except 5 p/ml

crude

retinal

factor

(Gitlin

and

D'Amore, 1983) was used instead of mouse sarcoma conditioned
medium.

BCE cells are usually maintained in Dulbecco's modified

Eagle's medium (DMEM), containing 25 pg/ml endothelial mitogen
(BTI), 10% calf serum, 2 mM glutamine, and antibiotics.

Endothelial Cell Rounding Assay on the

The samples to be tested

rounding assay were first dried

in a model

TM

100

SpeedVac Concentrator (Savant), and then dissolved in rounding
assay media (DMEM, 10% calf serum, 20 mM HEPES pH 7.4, 2 mM
glutamine

and antibiotics).

Bovine capillary endothelial

cells

were seeded onto 96 well half-area plates (0.16 cm2 wells )
(CoStar),

at a density of 2000 cells per 25 pi per well, in

rounding assay medium.

After a 6 - 12 hour attachment period,

the cells were treated with serial dilutions of inhibitor fractions
(Figure 3).

Cells were examined by phase microscopy after 6 - 24

hours, and judged for cell rounding.

One unit of cell rounding is

defined as the amount of sample which is sufficient to cause
rounding in 50% of the cells in a given well (Figure 41.

The

number of rounding units in a given sample is calculated from the
greatest dilution of sample which will produce one unit of cell
rounding.

'

DNA Synthesis Assay -

Bovine capillary endothelial cells

are plated on 48 well plates (CoStar) at a density of 7500
cells/well in DMEM containing 2% calf serum, 3 pM thymidine, 2
mM

glutamine,

and antibiotics.

After a 24

hour attachment

period, the medium is exchanged with rounding assay medium, the
samples are added, and the cells are incubated for an additional
18 hours at 37°C.

The cells are then incubated with 1 pCi 3H-

thymidine/well (82.2 Ci/mmol) for 6 h.
once

with

phosphate-buffered

saline

The cells are washed
(PBS).

The

cells

are

subjected twice to a wash of cold methanol for 5 minutes each
wash, and twice to cold 5% trichloroacetic acid for 10 minutes
each.

The plates are washed briefly with water and 0.3 M NaOH is

added.

The NaOH-solubilized material is transferred to vials

containing

scintillation fluid.

The sample

is neutralized with

glacial acetic acid, and the vials are counted in a Beckman model
LS 3801

scintillation counter.

Chick Chorioallantoic Membrane (CAM) Assay -

The CAM

assay is performed as described by Crum et al. (1985).

The

sample to be tested for stimulatory or inhibitory properties is
combined with a carrier of 0.45% methylcellulose (10 pi), and air
dried to form a disc of 2 mm diameter.

This disc is applied to the

shell-less embryo in a cultured petri dish (Auerbach et al., 1974;
Klagsbrun et al., 1976; Folkman, 1985).

After incubation at 37°C

in 3% CO2 for 48 hours, the embryos are examined under a
dissecting

microscope (6X power).

An embryo

is scored as

negative (indicating inhibition) if an avascular zone larger than 4

'

mm2 is observed (Figure 51.

Positive angiogenic activity is

revealed by the radical ingrowth of new vessels.

Inhibition or

stimulation of neovascularization can be confirmed by histologic
microsections

of

India-ink-injected

specimens

(Haudenschild,

1980).

PURIFICATION SCHEME

Dissection
removed,

were

-

Bovine eyes

obtained from

(-70°C), with the

BioResources,

Texas,

eyelids
and

the

corneas were dissected immediately upon arrival.

The eyeballs

were

the

rinsed

briefly

in

cold

distilled

H2O,

and

corneas

carefully excised from the frozen eyes, using a number 15 scalpel
blade (Figure 6).

The corneas were placed on dry ice, and stored

at -80°C until use.

Extractions

-

To begin the extraction

of CAI, frozen

corneas (500) were placed in a 1 liter Erlenmeyer flask, with 500
ml of HPLC grade H2O (Pierce HPLC grade solvents were used
exclusively throughout the purification).

The flask was put into a

hot water bath, brought to 100°C, and boiled for 20 minutes.

The

hot extract was filtered through coarse Whatman filter paper
under vacuum, to remove the corneas and debris.
centrifuged for 15 minutes at 10,000xg,
retained.

The filtrate was

and the supernatant

The supernatant was subjected to ultrafiltration using

an Amicon YM2 (1000 molecular weight cut-off) membrane under
55 psi nitrogen pressure, overnight at 4°C.

The filtrate was

collected

and

lyophilized.

The

reconstituted with 10 ml of H2O.

lyophilized

powder

was

Dimethylformamide (DMF, 90

ml) was added, and the solution stirred at room temperature for 1
hour.

The material was then centrifuged in glass tubes for 20

minutes at lO.OOOxg.

The supernatant was dried in a model EL

131 RotoVapor (Buchi).

DMF (25 ml) was added directly to the

round bottom RotoVapor flask, and the flask agitated at room
temperature for 1

hour.

This material was centrifuged for 20

minutes, and the supernatant retained and stored at 4°C.

High-Pressure Liquid Chromatography

C18 Analytical HPLC column - Initial investigation of the
binding

and

elution

of CAI was

performed

using

a

Supelco

octadecylsilica (Cl 8 reversed phase) analytical (15 cm X 4.6 mm)
HPLC column.
75mm

DMF extracted material (1 ml) was dried in 12 X

borosilicate tubes in

a SpeedVac

rotor

(Savant),

and

resuspended in 100 pi of H20, 0.1% trifluoroacetic acid. This
sample was injected onto the column, and washed with a complex
gradient of O -100% acetonitrile, 0. 1% trifluoroacetic acid (TFA)
(Figure 71.
Vac.

Fractions (2 ml) were collected, and dried in a Speed

Absorbance of the fractions eluting from the column

monitored at 220nm.

was

These fractions were saved for assay in the

endothelial cell rounding assay,

DNA synthesis inhibition, and

CAM assay.

C18 Semi-preparative HPLC column

-

A similar technique

was employed when using the Cl8 semi-preparative HPLC column.

The

100%

DMF

extracted

material

(3ml)

resuspended as above, in 0.1% TFA (200 pi).

was

dried

and

This sample was

injected onto a Cl8 semipreparative (25 cm X 10mm) HPLC column
(Supelco), and absorbance of eluted fractions again measured at
220 nm (Figure 81.

Fractions were collected and assayed for

bioactivity.

Cl8 Analytical HPLC column - second HPLC purification
step.

A single fraction (fraction 13) obtained from the Cl8 semi¬

preparative column which demonstrated the greatest number of
units of endothelial cell rounding activity was selected and dried.
This fraction was reconstituted in 100 pi of H20, injected onto a
Supelco C18 analytical (15 cm X 4.6mm) HPLC column (Supelco),
and eluted with a complex gradient of O - 50% acetonitrile, in the
absence

of

trifluoroacetic

acid

(Figure 91.

Fractions were

collected by hand, as individual peaks of absorbance seen at 220
nm.

These samples representing individual peaks of absorbance

were assayed for bioactivity using the endothelial cell rounding
assay, and the elution fractions which contained bioactivity were
determined.

This second HPLC purification step was repeated

under exact conditions, using identical starting sample material.
Identical (superimposable) chromatographs were obtained.

These

fractions were similarly collected by hand, as individual peaks,
and retained for mass spectroscopy investigations (Figure 10).

Mass Spectroscopy - As detailed in the previous section,
fractions

which

eluted

from

the

C18

analytical

column

.

purification step identically to those which had demonstrated
bioactivity were collected in pre-weighed 12 x 75 baked glass
tubes, dried in a SpeedVac, and submitted for structural analysis
to SmithKIine Beecham Pharmaceuticals (Michael Huddleston,
Steven A. Carr, Ph.D.).

Additionally, the fractions representing

absorptive peaks which did not demonstrate bioactivity were
submitted for comparative studies.

All samples were analyzed by

electrospray mass spectroscopy (ESMS), and bioactive fractions
were analyzed by desorptive chemical ionization (DCI) in both
positive and
isobutane

negative

as

the

ion

modes,

reagent

gases

using both
(Steven

ammonia and
Carr,

personal

bovine

capillary

communication).
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RESULTS

Previously, a method of extraction and partial purification
of CAI from bovine cornea was established by Susan Doctrow and
Ed Mun.

A schematic of their method is given in Table 4. and in

Table 5. a schematic of the improved purification method which
we

have established is presented.

In the previous scheme,

corneas purchased from BioResources were extracted in
ethanol, overnight in the cold.
bacterial overgrowth.

10%

Ethanol was employed to control

A second two hour extraction followed, and

the extract was boiled for 15 minutes after which the corneas
were removed by filtration.
a

MW

The extract was passed through a

membrane

with

cut-off

of

1000,

and

the

filtrate

lyophilized.

Two chloroform : methanol (50:50) extractions were

performed, and the soluble fraction was retained and dried on a
RotoVapor.
chromatography

Several
were

conditions
employed,

for
but

high

pressure

successful

binding

liquid
and

elution of the CAI activity could not be reproducibly achieved
with the chloroform:methanol extracted material.

We have developed an improved purification method for CAI.
In order to better control for the preparation and storage of our
starting material, we obtained frozen whole bovine eyes, and
dissected the corneas in our laboratory directly upon arrival from
BioResources. Next, the corneas were boiled in HPLC H2O for 20
minutes. The resultant extract yielded the same or higher amount
of rounding activity/cornea as the longer cold extraction of the

previous method, but had a lower protein content, and less visible
debris.

Significant advantages of this step are also the reduction

in time from 28 to 2 hours, and elimination of the need for
ethanol, which must be removed later in the purification.

The ultrafiltration step remains unchanged in the current
method.

This step yields an 80% recovery of rounding activity

after filtration (Table 6).

We have recently found that a second

ultrafiltration step, using a membrane with a 500 MW cut-off and
identical conditions, yields an 80% recovery of activity that had
been recovered after the first ultrafiltration step (1000 MW cut¬
off

filter).

The major modification in the current method is the organic
extraction performed.

In the current method, DMF is added to a

concentrated aqueous solution of the CAI, to produce a final
concentration of 90% DMF.
flocculent precipitate.

This instantly produces a large,

After centrifugation, almost 90% of the

rounding activity is recovered in the supernatant, and none is
detected in the pellet.

A subsequent 100% DMF extraction yields

more precipitated material, and 85 - 90% recovery of rounding
activity.

The

with

result

the

purification

results of these extractions compare favorably
of

the

methods.

organic
The

extraction

of

the

chloroform:methanol

previous
extraction

yielded only a 50% recovery of activity in the soluble fraction,
with a nearly equal amount of activity detectable in the insoluble
material, even after two overnight extractions.
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The

material

obtained

from

the

DMF

extractions

also

demonstrated the ability to inhibit DNA synthesis, as partially
purified CAI by the previous method did (Figure 11).

There is

significant inhibition of DNA synthesis, at concentrations of CAI
much less than required for rounding activity.

Similar results

had been found with the chloroform: methanol extracted material.

The most important outcome of the DMF extractions was
that with this material, we were able to establish conditions to
consistently bind and elute CAI activity from HPLC Cl 8 reverse
phase columns.

Figure 7 shows a chromatograph obtained by using

a Cl8 analytical column, and running a complex gradient from O to
100% acetonitrile, with 0.1% trifluoroacetic acid. Fractions were
collected and assayed for rounding activity. Fractions 2 - 14 all
showed some rounding activity, but two major peaks of activity
were demonstrated.

The early fraction were very acidic, with a

pH of 5 in the most concentrated samples in the cell rounding
assay.

In order to test if all the rounding activity seen in these

fractions correlated with anti-angiogenic activity, we tested the
fractions on the CAM assay.

The results are presented in Table 7.

Fractions from the Cl8 column were pooled into four groups.
1-4

and

rounding

10-13

showed

similar

activity, the other pools less.

toxic to the embryos, killing 4/5.
avascular zone.
dramatic

amounts

of

endothelial

Pool
cell

Pool 1-4 was clearly

The one surviving egg had no

In contrast, the pool of fractions 10-13 showed

anti-angiogenic

activity,
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with

5/5

large

avascular

.

zones.

The other pools showed no toxicity, and both demonstrated

some weak anti-angiogenic activity.

In order to increase the amount of CAI purified, we scaled
up the purification using a C18 semipreparative column.

The

larger column yielded better resolution and separation, again,
with two

major peaks of rounding

Interestingly,

the

fractions

activity seen

collected

from

this

(Fig ure Q).

column

which

were highly acidic were fraction 3 and 4, and no rounding activity
was seen in these fractions.

As the next step in the purification, a single fraction from
the semipreparative column containing high rounding activity was
selected, and run on the Cl8 analytical column.

A more gradual

gradient of acetonitrile, without TFA, was utilized, in an attempt
to

obtain

further separation

of the

bioactive

material.

The

resultant chromatograph contained only a few well-delineated
peaks,

and was found to

be

highly

reproducible,

run

under

identical conditions, using identical starting material (Figure 9T
The

peaks

seen

on

the

Cl 8

analytical

chromatograph

were

collected by hand, and dried in a SpeedVac.

Presumably identical

fractions were obtained from consecutive

runs:

one

set was

devoted towards assay for endothelial cell rounding activity, and
was

set

was

prepared

and

retained

for

analysis

by

mass

spectroscopy. The first and fifth peak (Figure 101 both showed
rounding

activity.
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Because

of

the

concern

of

possible

toxicity

in

the

bioactivity assays from the use of organic solvents throughout
the purification, a blank run of the entire purification scheme
was performed, and samples from each stage of the purification
were tested on the endothelial cell rounding assay.

All samples

demonstrated no cell rounding, and no toxicity to the cells was
observed.

These

blank samples,

purification

scheme,

were

also

produced
submitted

by following
with

the

the

active

samples for mass spectroscopy analysis, to rule out artifactual
results.

The
species

mass
of

spectroscopy

molecular

analysis

weight

228

showed
in

a

consistent

electrospray

mass

spectroscopy (ESMS) and desorptive chemical ionization (DCI).

A

gas phase exchange experiment indicated that the molecule has
three exchangeable hydrogens (H).
clouded

by

very

trifluoroacetate.
= 172).

strong

The electrospray data was

signals

derived

from

sodium

A unique peak was seen at m/z 173 (possible Mr

This signal, however, was not observed in the DCI, and

could not be pursued further.

Electrospray

and

DCI

mass

spectra

performed on blanks which had been submitted.
were

obtained

without the

by

performing

corneas.

the

It was

entire

concluded

was

These blanks

purification
that

also

the

scheme,
extraction

process and solvents were not contributing to the observations
which had been made about the active samples.
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Scanning

high

resolution was

next attempted

on

these

partially analyzed samples, however, the sample was found to be
inadequate,

secondary

either

degradation of the material.
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to

insufficient

quantity,

or

DISCUSSION

This
purification

paper

describes

of a

novel

the

corneal

described by Mun et al. (1989).

further

characterization

angiogenesis

inhibitor,

and

initially

Three different assays were used

to assess the bioactivity of partially purified samples of CAI.
Primarily,

BCE rounding activity has been

purification.

used to guide the

Retention of the ability to inhibit DNA synthesis by

BCE cells, and to generate avascular zones on the CAM has also
been demonstrated throughout the purification.

A major difficulty in the previous purification scheme was
the inability of the CAI partially purified by chloroforrmmethanol
extraction to reproducibly bind to and elute from an HPLC column.
The finding that CAI was soluble in DMF enabled the use of HPLC
for

further

purification

of the

molecule.

There

are

several

reasons why the DMF extraction facilitated HPLC purification.

The

DMF extraction could have removed contaminating impurities from
the CAI and enabled binding to the Cl8 column.

Alternatively, DMF

extraction could have caused a chemical alteration of the CAI
molecule, of a carrier, or an associated molecule.
seems

less

likely,

since

BCE

DNA synthesis

This alternative
inhibition,

BCE

rounding activity, and CAM angiogenesis inhibitory activity were
retained after both the DMF extraction and the HPLC Cl8 column
steps.
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Two clearly distinct peaks of rounding activity eluted
from both the analytical and semi-preparative Cl 8 HPLC columns
(Figures 7-9).

Pools of the fractions from the peaks observed on

the first analytical column separation were also analyzed for DNA
synthesis inhibition and angiogenesis inhibition on the CAM.
material

from the

later eluting

peak of rounding

cell

The

activity

clearly retained both the ability to inhibit BCE DNA synthesis, and
the ability to cause avascular zones in the CAM assay.

The early

eluting peak from the Cl8 column was found to have rounding
activity, and it inhibited BCE DNA synthesis.

This material did not

cause avascular zones on the CAM assay, however 4/5 of the
embryos

died

with

this

treatment,

suggesting

toxicity.

Investigation of the ability to inhibit angiogenesis in the CAM
assay has not yet been carried out with material from the Cl 8
semi-preparative column.
from

this

column

is

The first peak of rounding cell activity

better separated

from

the

absorbing material than with the analytical column.
that the

semi-preparative

column

might provide

bulk

of

UV-

It is possible
separation

of

cell-rounding activity from the material which was toxic on the
CAM assay.

If isolated from toxic substances, the material from

early peak of rounding cell activity may also inhibit angiogenesis
on the CAM assay.

This early eluting material could represent an

alternate form of the CAI.
dimer, or multimer.

It is possible that the CAI exists as a

Alternatively, a carrier molecule could be

associated with the CAI molecule.
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The second peak of cell rounding activity which eluted from
the Cl 8 column also demonstrated inhibition of DNA synthesis,
and inhibition of angiogenesis on the CAM, therefore this material
was selected for further purification.

Because of difficulty in

finding another HPLC resin to which the CAI would bind, the
ability of CAI to bind to C18 was further exploited.

A single

semi-preparative column fraction which demonstrated the highest
endothelial cell rounding activity (fraction 13) was selected, and
run on the Cl 8 analytical column under slightly different solvent
conditions.
for

the

Selection of a single fraction of the CAI activity peak

next

stage

of the

sacrifice of active material.

purification

entailed

a

significant

If all active fractions from the HPLC

column were recombined, this step involved about a 30% loss of
activity from the material loaded onto the column.

By selecting

only a single active fraction, only 5-10% of this activity was
utilized

in

the

next

step

of

purification.

Accepting

such

a

significant sacrifice of active material is an obvious disadvantage
to the purification scheme.

However, this method does yield a

high degree of purification which we hoped to be sufficient for
structural analysis.

The chromatograph obtained from the Cl8

analytical run of fraction 13 showed few well-delineated peaks
(Figure 10).
fraction

13

Multiple runs of the C18 analytical column, using
from

multiple

runs

of

the

column, provided identical chromatographs.

C18

semi-preparative

These peaks were

collected as separate fractions for examination
Endothelial cell

of bioactivity.

rounding activity was observed in two of the

fractions collected from the column (peaks 1 and 5).
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Because the

peaks from the analytical column eluted sharply and seemed to
represent single species, it was decided that this material might
be pure enough for further analysis by mass spectroscopy and that
valuable

structural

analysis.

information

might

be

obtained

from

this

There was not enough material accumulated from the

Cl8 analytical column to also establish anti-angiogenic activity
on the CAM assay.

This work is in progress.

By mass spectroscopy, possible candidates for the active
CAI molecule were found at MW 228 and 172.

The 228 species was

also found in desorptive chemical ionization.

Gas exchange was

employed

to

show

that

this

molecule

had

3

exchangeable

hydrogens (by comparison with NH3 or ND3 as the reagent gases),
and possible alcohol functions (mass 18 losses).
deoxyuridine fits this description.

The molecule 2-

Therefore this compound was

assayed for BCE rounding activity at concentrations up to 10 mM.
No rounding activity was observed.

However, it is possible that

CAI may be co-purified with a carrier or associated molecule
which may be required for bioactivity.

One approach to test this

theory would be to add 2-deoxyuridine to samples of CAI with
known activity, and look for enhancement of the bioactivity.

Characterization
information.

of the

molecule

has

revealed

It is a molecule of very low molecular weight.

stable to boiling and freezing.
digestion.

CAI

new
It is

It has shown resistance to pronase

Furthermore, sensitive amino acid analysis indicates

that it is not a peptide.

On the other hand,
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solubility and

chromatography behaviors of the CAI molecule are consistent with
those of a polar lipid.
candidates
glycolipids,
that

for

the

Based on these characteristics, possible
identity

of

CAI

or their metabolites.

these

molecules

can

include

sphingolipids,

Recent reports demonstrate

perform

roles

in

regulation

of

vascularization.

Sphingolipids and sphingolipid breakdown products have been
shown to have important roles in cell regulation and physiology
(Hannun and Bell, 1989).
these

cellular

lipids

Breakdown products and metabolites of

include

arachadonic

acid,

prostaglandins,

leukotrienes eicosanoids, thromboxanes (Needleman et ai, 1986;
Samuelsson

et ai, 1987), and diacylglycerol (Nishizuka,

1986).

These molecules may function as endogenous modulators of cell
function (Hannun and Bell, 1989).

Prostaglandins Ei and E2 have

been demonstrated as nonpeptide angiogenic factors (BenEzra,
1978: Ziche et ai, 1982; Form and Auerbach, 1983), and proposed
to have a role in rheumatoid arthritis, tumor induced angiogenesis,
and lymphocyte induced angiogenesis (Form and Auerbach, 1983).
The role of prostaglandins in the eye is not well known; however a
recent study of the influence of a fish oil dietary supplement on
immunogenic

keratitis

has

looked

(Verby and Van Haeringen, 1990).

indirectly

at

this

question

In this study, rabbits were given

either a fish oil diet, or a sunflower seed oil diet, before immune
complex keratitis was induced by corneal intrastromal injection
of human serum albumin.

Fish lipids are known to contain large

amounts of eicosapentaenoic acid (EPA) and docosahexaenoic acid.
28

These fatty acids are known to have an effect on prostaglandin and
leukotriene synthesis.

The sunflower seed diet is rich only in

linoleic acid, which does not influence the production of either
prostaglandins or leukotrienes.
fish

oil

diet

showed

leukocyte infiltrate,

The animals which were given the

significantly

less

neovascularization,

and corneal edema, as compared to the

animals fed a sunflower seed oil diet.

This study provides a

provocative inference that eicosanoids, either prostaglandins or
leukotrienes, may play an important role in the inhibition of
angiogenesis in the cornea.

An arachadonic acid metabolite produced by the cornea has
been recently described as a potent, dose dependent, chemotactic
and angiogenic factor (Masferrer et al., 1991).
from human and bovine corneal epithelium
convert

arachadonic

acid

to

Cytochrome P450

have been shown to

12(R)-hydroxy-5,8,14(Z,Z,Z)-

eicosatrienoic acid (compound D) (Masferrer et al., 1989) (Murphy
et al.,

1988).

This

metabolite

has

inflammatory

properties

including stimulation of vasodilation and breakdown of the bloodaqueous barrier (Masferrer et al., 1989).

Human, bovine, and rabbit

corneas have also been shown to metabolize arachadonic acid to
12(R)-hydroxy-5,8,10,14 eicosatetraenoic acid [12(R)HETE], which
is an inhibitor of Na+-K+-ATPase (Schwartzman et al., 1987).

The

actual role of this molecule in the cornea has not been described.
Again, given the characteristics of the partially purified CAI,
further investigation in the potential relationship to the corneal
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cytochrome

P450

arachadonic

acid

metabolites

is

certainly

warranted.

In summary, a reproducible and straightforward method of
extraction and partial purification of CAI from bovine cornea has
been

established.

Successful

purification

of

an

angiogenesis

inhibitor from cornea is of great potential significance.
it

is

of

low

molecular

weight

and

naturally

Because

occurring,

this

compound has the potential to serve as a diffusible, non-antigenic
treatment

of

corneal

neovascularization

angiogenic-dependent diseases.

and

possibly,

of

other

Another potential use of purified

CAI might be to improve the storage of corneas prior to corneal
transplant.

It is well known that there

endothelial
which the
1973).

rejection

and graft failure

is a high

in

corneal

recipient beds are vascularized

transplants

is high

A storage solution containing added CAI

prevent

neovascularization

incidence of

of the transplanted

in

(Khodadoust,
might help tp

corneas.

This

exogenously added CAI could diffuse into the cornea and make it
less angiogenic.
can

In the current aqueous solutions, endogenous CAI

presumably diffuse out of the

stored cornea and

into the

storage solution, leaving bFGF in Bowman's layer and Descemet's
membrane,
Finally,

which

discovery

compound

may

counteracting

can
of

help

lead
the

to

structure

elucidate

angiogenic

increased

factors

the

of

neovascularization.
this

mechanism

such

as

anti-angiogenic
of

bFGF.

its
It

role
is

in

quite

possible that the same or very similar compounds may be found in
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many other tissues of the body, functioning in the regulation of
vascularization.
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T^ILE

H

DISEASES MANIFESTING PATHOLOGIC ANGIOGENESIS

Ophthalmology
Corneal graft neovascularization
Diabetic retinopathy
Neovascular glaucoma
Trachoma
Retrolental fibroplasia
internal Medicine
Arth ritis
Scleroderma
Pediatrics
Hemophiliac joints
Angiofibroma
Hemangioma
Radiology
Arteriovenous malformations

Orthopedics
Nonunion fractures
Oncology
Solid tumors
Surgery
Granulations-burns
Vascular adhesions
Hypertrophic scars
Delayed wound healing
Dermatology
Psoriasis
Pyogenic granuloma
Neurology
Osler-Weber Syndrome
Cardiology
Atherosclerotic plaques

TABLE 1 - This table represents a group of
diseases previously thought to be unrelated, however,
it has been recognized that the principle pathologic
feature of each of these conditions is the abnormality
of capillary blood vessel growth.
Furthermore, there
is the possibility that therapeutic control of the
abnormal capillary growth could eliminate other
manifestations of the disease.
(Adapted
from
Klagsbrun and Folkman, Angiogenesis. Handbook of
Experimental Pharmacology. Vol. 95(11), Chapter 37,
1990).
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TABLE 2 - Capillary growth into the normally avascular
cornea can result in decreased vision or blindness in the above
disease states.
Disorders can involve either the corneal
epithelium, corneal stroma, or both tissues.

DISORDERS ASSOCIATED WITH CORNEAL NEOVASCULARIZATION
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PURIFIED ANGIOGENIC FACTORS

GROWTH FACTOR

MOLECULAR WEIGHT

Basic FGF
Acidic FGF
VEGF
Angiogenin
TGF - a

18
16
45
14
5

000
500
000
100
500

TGF - p

25 000

TNF - a
Platelet-derived ECGF
Angiotropin
1 -Butyryl-glycerol

17 000
45 000
4 500
306

TABLE 3 - These factors have been shown to be
angiogenic in vivo, and include polypeptide and
nonpeptide low molecular weight compounds (Dobson
et a!., 1990; Rosenthal et al., 1990; Klagsbrun and
Folkman, 1990).
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TABLE 4

CAI PREVIOUS PURIFICATION METHOD

Extract frozen bovine corneas in 10% ethanol, 24 hrs,4°C
Filter to remove corneas
Re-extract corneas in 10% ethanol, 2 hrs, 4°C, filter
Boil filtrates,

10 min, centrifuge

Evaporate ethanol on Rotovapor, 1 hr
Ultrafiltration

of supernatant,
Lyophilize

1000MW

cut-off filter

filtrate

Extract in 1:1 chloroform:methanol, 18-24 hrs, 25°C, centrifuge
Re-extract pellet in 1:1 chloroform:methanol, 2 hrs, 25°C, centrifuge
Combine supernatants from chlorofornrmethanol extractions
Dry on RotoVapor

TABLE

4 - A method of extraction and partial

purification of CAI from bovine cornea established by
Susan Doctrow and Ed Mun is presented above.
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CAI CURRENT PURIFICATION METHOD

Extract frozen bovine corneas in 100°C distilled H2O, 20 min
Filer to remove corneas, centrifuge filtrate
Ultrafiltration

of supernatant,
Lyophilize

1000MW

cut-off filter

filtrate

Extract in 90% dimethylformamide (DMF), 1 hr, 25°C
Centrifuge, dry supernatant on RotoVapor
100% DMF extraction, 1 hr, 25°C
Dry extract in Speed Vac
FIPLC Cl8 Semi-preparative column
Elute with 0 - 100% acetonitrile, 0.1% trifluoroacetic acid
HPLC Cl8 Analytic column
Elute with 0 - 50% acetonitrile

TABLE

5

-

This schematic represents the
current CAI partial purification method.
This method
has demonstrated improvement in reproducibility,
and
more significantly, DMF extraction of CAI has allowed
for consistent utilization of FIPLC to obtain further
purification.

.

ACTIVTY YIELDS OF THE CURRENT CAI PURIFICATION

Boiling

Extraction

100%

Ultrafiltration

80%

90% DMF Extraction

90%

100% DMF Extraction

85%

Semi-preparative Cl 8 HPLC
- all active fractions totaled

70%

Single fraction (13) - selected for
further HPLC purification

5-10%

Cl8 analytical HPLC column
- total of active fractions

80%

TABLE 6 - The above table presents the approximate
yields of activity of each step in the purification
scheme.
Activity is based on observed bioactivity in
the semi-quantitative BCE rounding cell assay.
Activities were calculated as the % of activity
retrieved from the total activity of the starting
material from the previous step.
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TABLE 7

ANTI-ANGIOGENIC ACTIVITY OF Cl8 HPLC FRACTIONS

CHICK CHORIOALLANTOIC MEMBRANE ASSAY

% Avascular
Zones

08
Fractions

Rounding
Units

I - 4*

126

0 %

5-9*

81

20 %

10 - 13*

114

100 %

14 - 16’

18

40 %

Observations

Toxic to 4/5 eggs

1/5 small zone

5/5 large avascular

2/5 small zones

Fractions pooled from 6 runs of CIS HPLC analytical column

TABLE 7 - Fractions collected from a sample of
100% DMF extracted CAI material run on a Cl8
analytic HPLC column (Figure 7) were pooled into
four groups: Fractions 1-4, 5-9, 10-13, 14-16.
The
samples were assayed for BCE rounding activity and
angiogenesis inhibition on the CAM.
The pool of
fraction 10-13 showed dramatic anti-angiogenic
activity, and high BCE rounding activity.
38
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FIGURE 1

SCHEMATIC REPRESENTATION
OF THE VASCULAR AND AVASCULAR STRUTURES
OF THE BOVINE AND HUMAN EYE

CORNEA

FIGURE 1 - The eye is divided into vascular
and avascular zones.
The cornea, lens, sclera,
aqueous humor and vitreous humor are all normally
avascular zones.
Infringement of blood vessel
growth into these tissues can lead to decreased
vision or blindness (Diagram adapted from
Goldberg, 1984).
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FIGURE 2

SCHEMATIC REPRESENTATION OF
HISTOLOGIC SECTIONS OF THE CORNEA

CORNEAL EPITHELIUM*,

r/-^

sTTfsP ~f

BOWMAN'S" MEMBHANeT*7--

_=r

STROMA

descemet's membrane^
'endothelium^

FIGURE 2 - Bowman's layer is the acellular,
anterior-most portion of the collagenous corneal
stroma,
rich
in
heparan-sulfate
proteoglygan.
Descemet's membrane is a true basement membrane
produced by corneal endothelial cells on the posterior
surface of the cornea. Both layers bind bFGF (Adamis
et a/., 1991; Diagram adapted from Goldberg, 1984).
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CAI TREATED BOVINE
CAPILLARY ENDOTHELIAL CELLS

FIGURE 4 - Bovine capillary endothelial cells were
plated at a density of 2000 cells per 25 pi per well, in 96
well 1/2 area plates. These cells were treated with serial
dilutions
of
CAI
inhibitor
samples
(decreasing
concentrations from left to right).
The inhibitor causes
rounding of the cells after 10-24 hours, in a concentration
dependent manner. One unit of cell rounding as defined as
the amount of sample sufficient to cause rounding of 50% of
the cells in a given well. The cells in the middle well above
would be scored as 50% round. The rounded cells exclude
trypan blue and stain with the viability marker fluorescein
diacetate

42

FIGURE 5
CAI INHIBITION OF ANGIOGENESIS ON THE
CHICK EMBRYO CHORIOALLANTOIC MEMBRANE

FIGURE 5 - Application of a sample of partially
purified CAI to the chorioallantoic membrane of a sixday chick embryo causes capillary regression and
produces a 4 mm avascular zone at 48 hrs, indicating
inhibitory activity.
The chick embryo was injected
with India ink prior to dissection to improve
visualization of the vessels. (Photo courtesy of Susan
Doctrow and Ed Mun).
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BOVINE CORNEA DISSECTION

FIGURE 6 - Bovine eyes (-70°C) were rinsed
briefly in cold distilled H2O, and the cornea carefully
excised from the frozen eye using a number 15 scalpel
blade. The corneas were placed on dry ice and stored
at -80°C.
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FIGURE 7
C18 ANALYTIC HPLC COLUMN
100% DMF EXTRACTED CAI SAMPLE

Cl 8

Analytical

Column

at

o

Absorbance

units

5

Units

0

Rounding Activity

2 20nm

5

Fractions

FIGURE 7 - This chromatograph was obtained
with a sample of CAI which had been extracted in
100% DMF. CAI rounding cell activity was found to
consistently bind and elute from the Cl8 analytic
column as shown above. Two major peaks of rounding
cell activity were observed, and fractions from both
peaks also inhibited BCE DNA synthesis.
Only the
second peak, however, was shown to have angiogenic
inhibitory capability on the CAM assay.
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FIGURE 8
C18 SEMIPREPARATIVE HPLC COLUMN
100% DMF EXTRACTED CAI SAMPLE

SEMI-PREPARATIVE COLUMN

Absorbance

at

Rounding Units

220nm

Cl 8

Fractions

FIGURE 8 - In order to increase the amount of
CAI purified using Cl 8 HPLC, a semipreparative Cl 8
HPLC column was employed. Using the larger column,
better resolution and separation of CAI bioactivity
was obtained.
As with the analytical column, two
major peaks of BCE rounding activity were observed.
Notably, fractions 3 and 4 collected from this column
were highly acidic, but contained no rounding activity.
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FIGURE 9
C18 ANALYTICAL HPLC COLUMN
SECOND HPLC PURIFICATION STEP

Cl 8 Analytical HPLC Column
se-mi—preparative

column

fraction

13

Acetonitrile

Absorbance at 220 nm

C 18

minutes

FIGURE 9 - To further the purification of CAI, a
single fraction from the Cl 8 semi-preparative column
(Fraction 13) which contained high BCE rounding
activity (Figure 8) was selected, and run on a Cl8
analytical column, with a 0 - 50% gradient of
acetonitrile (no TFA). The above chromatograph was
obtained, and the individual peaks collected as
separate fractions and assayed for bioactivity.
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HGURE 10
CIS ANALYTICAL HPLC COLUMN
BIOACTIVITIES AND WEIGHTS OF SAMPLES
SUBMITTED FOR MASS SPECTROSCOPY

FIGURE
10 - Fractions were collected as
marked on the chromatograph (1 - 5), and assayed for
rounding activity.
Fraction 1 contained 7 units of
rounding activity, fraction 5 contained 6 units.
Another run was performed under identical
conditions, and these same fractions were collected
in baked glass tubes, dried in the SpeedVac, and
weighed.
These samples were submitted for mass
spectroscopy, with samples 1 and 5 corresponding to
active fractions.

48

FIGURE 11
EFFECT OF CAI ON BCE DNA SYNTHESIS

o-o 50 jj,\
• -• 200
* cells rounded

BCE DNA Synthesis (dpm x 10

3)

fi\

FIGURE 11 - CAI partially purified by DMF
extraction which had demonstrated bioactivity in the
BCE rounding assay was assayed for bioactivity in a
DNA synthesis experiment.
The DMF extracted CAI
sample demonstrated significant inhibition of DNA
synthesis, at concentrations of CAI much less than
required for rounding activity.
Similar results had
been obtained with the chloroform:methaol extracted
material from the previous purification scheme.
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